Decision Criteria for Partial Nationalization of Pharmaceutical Supply Chain: A Scoping Review

Patrícia Véras Marrone (), Fabio Rampazzo Mathias, Wanderley Marques Bernardo, Marina Feliciano Orlandini, Maria Carolina Andrade Serafim, Maria Lídia Rebello Pinho Dias Scoton, Juliano Marçal Lopes, Sérgio Luiz Pereira and Eduardo Mario Dias ()
Additional contact information
Patrícia Véras Marrone: Faculdade de Economia e Administração, and Escola Politécnica de Engenharia, University of São Paulo, São Paulo 05508-010, SP, Brazil
Fabio Rampazzo Mathias: Electrical Engineering, Escola Politécnica de Engenharia, University of São Paulo, São Paulo 05508-010, SP, Brazil
Wanderley Marques Bernardo: Medicine School, University of São Paulo, São Paulo 01246-903, SP, Brazil
Marina Feliciano Orlandini: Santos Medical Sciences Faculty, Centro Universitário Lusíada, UNILUS, Santos 11015-300, SP, Brazil
Maria Carolina Andrade Serafim: Santos Medical Sciences Faculty, Centro Universitário Lusíada, UNILUS, Santos 11015-300, SP, Brazil
Maria Lídia Rebello Pinho Dias Scoton: Electrical Engineering, Escola Politécnica de Engenharia, University of São Paulo, São Paulo 05508-010, SP, Brazil
Juliano Marçal Lopes: Electrical Engineering, Escola Politécnica de Engenharia, University of São Paulo, São Paulo 05508-010, SP, Brazil
Sérgio Luiz Pereira: Electrical Engineering, Escola Politécnica de Engenharia, University of São Paulo, São Paulo 05508-010, SP, Brazil
Eduardo Mario Dias: Electrical Engineering, Escola Politécnica de Engenharia, University of São Paulo, São Paulo 05508-010, SP, Brazil

Economies, 2023, vol. 11, issue 1, 1-21

Abstract: (1) Background: Any disturbance in the pharmaceutical supply chain (PSC) can disrupt the supply of medicines and affect the efficiency of health systems. Due to shortages in the global pharma supply chain over the past few years and the complex nature of free trade and its limitations when confronted by a major global health and humanitarian crisis, many countries have taken steps to mitigate the risks of disruption, including, for example, recommending the adoption of a plus one diversification approach, increasing safety stock, and nationalizing the medical supply chains. (2) Objective: To scope findings in the academic literature related to decision criteria to guide national policy decisions for the “Partial Nationalization of Pharmaceutical Supply Chain” (PNPSC) from the viewpoints of the three main stakeholders: industry, payers (government and health insurance), and patients. (3) Methods: These consist of a scoping review of the peer-reviewed literature. (4) Results: A total of 115 studies were included. For local manufacturing decisions, five criteria and 15 sub-criteria were identified. Weighting, decision-making, risk assessment, and forecasting were the main data analysis tools applied; (5) Conclusions: The findings could serve as a baseline for constructing PNPSC frameworks after careful adaptation to the local context.

Keywords: PSC; pharmaceutical supply chain; healthcare; reshoring; nationalization; local production; API; active pharmaceutical ingredient; pharmaceuticals; drugs; medicines (search for similar items in EconPapers)
JEL-codes: E F I J O Q (search for similar items in EconPapers)
Date: 2023
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/2227-7099/11/1/25/pdf (application/pdf)
https://www.mdpi.com/2227-7099/11/1/25/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jecomi:v:11:y:2023:i:1:p:25-:d:1033247

Access Statistics for this article

Economies is currently edited by Ms. Hongyan Zhang

More articles in Economies from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().